Versigent officer trust plans $10.4M share sale

A trust associated with an officer plans to sell 220,000 Versigent PLC shares under a Rule 10b5-1 trading plan through Goldman Sachs.

Available on EDGAR 09/08/2026 - 06:28 PM EDT Accepted by SEC EDGAR 09/08/2026 - 06:28 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Versigent PLC (VGNT) has a planned secondary sale of common stock by an affiliate. A total of 220,000 shares of Versigent common stock, with an aggregate market value of $10,425,800, are to be sold on the NYSE through Goldman Sachs & Co. LLC on behalf of the Kevin P. Clark 2002 Revocable Trust. The notice states that these sales are made under a selling plan dated June 3, 2026 intended to comply with Rule 10b5-1(c). Versigent had 70,835,265 shares outstanding of common stock at the time referenced.

Key Figures

Shares to be sold: 220,000 shares Aggregate market value of shares: $10,425,800 Shares outstanding: 70,835,265 shares +3 more

6 metrics

Shares to be sold 220,000 shares Common stock to be sold under the Form 144 notice

Aggregate market value of shares $10,425,800 Market value of the 220,000 Versigent common shares covered by the notice

Shares outstanding 70,835,265 shares Versigent common stock outstanding at the time referenced

Planned sale date September 8, 2026 Date associated with the planned NYSE sale of the shares

Rule 10b5-1 selling plan date June 3, 2026 Date of the selling plan intended to comply with Rule 10b5-1(c)

Number of compensation grants listed 13 grants Separate executive compensation common stock entries from 2014 to 2026

Key Terms

Rule 144, Rule 10b5-1(c), selling plan, Revocable Trust

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Rule 10b5-1(c) regulatory

"a selling plan dated 06/03/2026 that is intended to comply with Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

selling plan financial

"made in connection with a selling plan dated 06/03/2026"

Revocable Trust financial

"220,000 shares to be sold by Kevin P. Clark 2002 Revocable Trust."

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Versigent PLC (VGNT) disclose in this Form 144?

The filing discloses a planned sale of 220,000 shares of Versigent PLC common stock on the NYSE by the Kevin P. Clark 2002 Revocable Trust, with an aggregate market value of $10,425,800, acting through Goldman Sachs & Co. LLC.

Who is selling Versigent (VGNT) shares and through which broker?

The Kevin P. Clark 2002 Revocable Trust plans to sell the shares, with Goldman Sachs & Co. LLC listed as the broker handling the sale of 220,000 common shares of Versigent PLC.

How many Versigent (VGNT) shares are planned to be sold and what is their value?

The notice covers 220,000 shares of Versigent PLC common stock with an aggregate market value of $10,425,800. These shares are expected to be sold on the NYSE.

What trading plan applies to the Versigent (VGNT) share sale?

The filing states that the sales are made in connection with a selling plan dated June 3, 2026 that is intended to comply with Rule 10b5-1(c), providing for pre-arranged trading parameters.

How many Versigent (VGNT) shares were outstanding at the time referenced?

Versigent PLC reports that there were 70,835,265 shares of common stock outstanding, providing context for the planned sale of 220,000 shares covered by this Form 144 notice.

What is the relationship of the seller to Versigent PLC (VGNT)?

The seller is identified as the Kevin Clark account, with the role indicated as Officer. The shares to be sold are held by the Kevin P. Clark 2002 Revocable Trust and were originally acquired as executive compensation on multiple dates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001248750
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	VERSIGENT PLC
SEC File Number	001-42957
Address of Issuer	Spitalstrasse 5 Schaffhausen SWITZERLAND 8200
Phone	41-58-515-1200
Name of Person for Whose Account the Securities are To Be Sold	Kevin Clark
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	220000	10425800	70835265	09/08/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/17/2014	Executive Compensation	Issuer			2695	02/17/2014	Compensation
Common Stock	02/16/2015	Executive Compensation	Issuer			21677	02/16/2015	Compensation
Common Stock	02/12/2016	Executive Compensation	Issuer			19837	02/12/2016	Compensation
Common Stock	02/17/2017	Executive Compensation	Issuer			18494	02/17/2017	Compensation
Common Stock	12/06/2017	Executive Compensation	Issuer			7500	12/06/2017	Compensation
Common Stock	02/16/2018	Executive Compensation	Issuer			12036	02/16/2018	Compensation
Common Stock	12/11/2018	Executive Compensation	Issuer			3770	12/11/2018	Compensation
Common Stock	02/28/2019	Executive Compensation	Issuer			28861	02/28/2019	Compensation
Common Stock	02/28/2020	Executive Compensation	Issuer			39545	02/28/2020	Compensation
Common Stock	02/28/2023	Executive Compensation	Issuer			22077	02/28/2023	Compensation
Common Stock	02/28/2024	Executive Compensation	Issuer			13258	02/28/2024	Compensation
Common Stock	09/10/2024	Executive Compensation	Issuer			4817	09/10/2024	Compensation
Common Stock	09/11/2024	Executive Compensation	Issuer			5091	09/11/2024	Compensation
Common Stock	02/28/2025	Executive Compensation	Issuer			14737	02/28/2025	Compensation
Common Stock	02/28/2026	Executive Compensation	Issuer			5605	02/28/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The sales of shares set forth herein are made in connection with a selling plan dated 06/03/2026 that is intended to comply with Rule 10b5-1(c). 220,000 shares to be sold by Kevin P. Clark 2002 Revocable Trust.
Date of Notice	09/08/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/03/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Goldman Sachs & Co. LLC on behalf of Kevin Clark
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)